Brian JG Pereira - Feb 4, 2025 Form 4 Insider Report for PROKIDNEY CORP. (PROK)

Role
Director
Signature
/s/ Todd Girolamo, attorney in fact
Stock symbol
PROK
Transactions as of
Feb 4, 2025
Transactions value $
$0
Form type
4
Date filed
2/6/2025, 04:05 PM
Previous filing
Oct 4, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PROK Class A Ordinary Shares Conversion of derivative security $0 +81.9K $0.00 81.9K Feb 4, 2025 Direct
transaction PROK Class A Ordinary Shares Conversion of derivative security $0 +675K $0.00 675K Feb 4, 2025 By Brian J. G. Pereira 2012 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PROK Class B Ordinary Shares Conversion of derivative security $0 -81.9K -50% $0.00 81.9K Feb 4, 2025 Class A Ordinary Shares 81.9K $0.00 Direct F1, F2
transaction PROK Common Units in ProKidney LP Conversion of derivative security $0 -81.9K -50% $0.00 81.9K Feb 4, 2025 Class A Ordinary Shares 81.9K $0.00 Direct F3
transaction PROK Class B Ordinary Shares Conversion of derivative security $0 -675K -50% $0.00 675K Feb 4, 2025 Class A Ordinary Shares 675K $0.00 By Brian J. G. Pereira 2012 Irrevocable Trust F1, F2
transaction PROK Common Units in ProKidney LP Conversion of derivative security $0 -675K -50% $0.00 675K Feb 4, 2025 Class A Ordinary Shares 675K $0.00 By Brian J. G. Pereira 2012 Irrevocable Trust F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Class B Ordinary Shares and the Common Units in ProKidney LP (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each filed as an Issuer's Annual Report on Form 10-K filed on March 22, 2024), each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for Class A Ordinary Shares on a one-for-one basis.
F2 The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.
F3 The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.